Hidden Targets in Cancer Immunotherapy: The Potential of "Dark Matter" Neoantigens

Area of Science:

• Oncology
• Immunology
• Genomics

Background:

• Cancer immunotherapies have advanced treatment but often fail to provide durable, tumor-specific responses.
• Neoantigens, peptides from tumor-specific mutations, are key targets for personalized cancer vaccines.
• Current strategies primarily target canonical neoantigens from single nucleotide variants and small insertions/deletions.

Purpose of the Study:

• To review the biology of non-canonical neoantigens.
• To discuss technological advancements for detecting these neoantigens.
• To explore their potential in next-generation personalized cancer vaccines.

Main Methods:

• Literature review of non-canonical neoantigen biology.
• Analysis of technological advances in neoantigen detection.
• Evaluation of clinical trial data for neoantigen-based vaccines.

Main Results:

• Non-canonical neoantigens arise from alternative splicing, intron retention, non-coding RNA translation, gene fusions, and retroelement activation.
• These neoantigens expand the antigenic landscape beyond canonical sources.
• Early trials show feasibility and potential survival benefits of neoantigen targeting.

Conclusions:

• Non-canonical neoantigens represent a largely untapped resource for cancer vaccines.
• Systematic detection technologies are emerging for these novel targets.
• Harnessing non-canonical neoantigens could significantly enhance the efficacy and specificity of personalized cancer vaccines.